The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key U.S. market.
In this article
Novo Nordisk
’s U.S. shares plummeted late Tuesday after the company said it sees sales and profit growth declining this year, expecting a sales hit.
The company published the forecast as it reported full-year 2025 sales, ahead of the quarterly report expected Wednesday morning.
Novo’s American depositary shares fell 11%.
Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026
Las acciones de Novo Nordisk se desploman ante la previsión de una fuerte caída de las ventas de Ozempic y Wegovy este año
Wegovy-maker Novo Nordisk warns of 'painful' price cuts as shares slump
